SCHEMBL22378741

SCHEMBL22378741

N#Cc1cccc(-n2c3ccccc3c3ccccc32)c1-c1cccc(-c2cccc(-n3c4ccccc4c4c(C#N)cccc43)c2)c1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
HIF1A Q16665 1/20 0.33
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
IMPDH2 P12268 1/20 0.30
MAOA P21397 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22378410 1.00 KDM4E (0.35) KDM4EATML3MBTL1SMN1; SMN2HIF1A
SCHEMBL22152676 0.95 KDM4E (0.35) KDM4EATML3MBTL1SMN1; SMN2HIF1A
SCHEMBL22154159 0.95 KDM4E (0.35) KDM4EATML3MBTL1SMN1; SMN2HIF1A
SCHEMBL22153471 0.94 KDM4E (0.34) KDM4EATML3MBTL1SMN1; SMN2HIF1A
SCHEMBL22377898 0.94 KDM4E (0.34) KDM4EATML3MBTL1SMN1; SMN2HIF1A
SCHEMBL22377671 0.94 KDM4E (0.34) KDM4EATML3MBTL1SMN1; SMN2HIF1A
SCHEMBL22152696 0.94 KDM4E (0.34) KDM4EATML3MBTL1SMN1; SMN2HIF1A
SCHEMBL22377551 0.94 KDM4E (0.39) KDM4EATML3MBTL1SMN1; SMN2HIF1A
SCHEMBL26614023 0.94 DHFR (0.32) KDM4EATML3MBTL1SMN1; SMN2HIF1A
SCHEMBL26614268 0.94 DHFR (0.32) KDM4EATML3MBTL1SMN1; SMN2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11800797-B2 Heterocyclic compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-10-24 US disclosed
US-11800797-B2 Heterocyclic compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-10-24 US disclosed
US-20200274074-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200274074-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CYP1A1, CRY2 KDM4E 3290/4885ATM 3429/4885L3MBTL1 1164/4885
US-11800797-B2 Heterocyclic compound and organic light-emitting device including the same CRY1, CYP1A1, CRY2 KDM4E 3290/4885ATM 3429/4885L3MBTL1 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.